What is claimed is:

- 1. A purified and isolated PDE10 polypeptide.
- The polypeptide according to claim 1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 18. SEO ID NO: 20 and SEO ID NO: 22.
- A polynucleotide encoding the polypeptide according to claim 1 or 2
- The polynucleotide according to claim 3 comprising the sequence set forth in SEQ ID NO: 1.
- A polynucleotide encoding a human PDE10 polypeptide selected from the group consisting of:
 - a) the polynucleotide according to claim 4;
 - a DNA which hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (a); and
 - c) a DNA which would hybridize to the non-coding strand of the polynucleotide of (a) but for the redundancy of the genetic code.
- The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO: 18.
- 7. The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO: 20.

- The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO: 22.
 - 9. The polynucleotide of claim 5 which is a DNA molecule.
 - 10. The DNA of claim 9 which is a cDNA molecule.
- The DNA of claim 9 which is a wholly or partially chemically synthesized DNA molecule.
- $12. \qquad \mbox{A polynucleotide comprising the sequence set out in SEQ} \label{eq:sequence}$ ID NO: 1 or a fragment thereof.
- A polynucleotide comprising the sequence set out in SEQ ID NO: 18 or a fragment thereof.
- A polynucleotide comprising the sequence set out in SEQ ID NO: 20 or a fragment thereof.
- A polynucleotide comprising the sequence set out in SEQ ID NO: 22 or a fragment thereof.
- 16. An anti-sense polynucleotide which specifically hybridizes with the complement of the polynucleotide of claim 5.
- $17. \hspace{0.5cm} \hbox{A expression construct comprising the polynucleotide} \\ \mbox{according to claim 5}.$
- A host cell transformed or transfected with the expression construct according to claim 17.

- A method for producing a PDE10 polypeptide comprising the steps of:
 - a) growing the host cell according to claim 18 under conditions appropriate for expression of the PDE10 polypeptide and
 - b) isolating the PDE10 polypeptide from the host cell or the medium of its growth.
- 20. An antibody specifically immunoreactive with the polypeptide according to claim 1 or 2.
- 21. The antibody according to claim 20 which is a monoclonal antibody.
- A hybridoma which produces the antibody according to claim 21.
- An anti-idiotype antibody specifically immunoreactive with the antibody according to claim 21.
- 24. A method to identify a specific binding partner compound of the PDE10 polypeptide according to claim 1 or 2 comprising the steps of:
 - a) contacting the PDE10 polypeptide with a compound under conditions which permit binding between the compound and the PDE10 polypeptide;
 - b) detecting binding of the compound to the PDE10 polypeptide; and
 - identifying the compound as a specific binding partner of the PDE10 polypeptide.

- 25. The method according to claim 24 wherein the specific binding partner modulates activity of the PDE10 polypeptide.
- The method according to claim 25 wherein the compound inhibits activity of the PDE10 polypeptide.
- The method according to claim 25 wherein the compound enhances activity of the PDE10 polypeptide.
- 28. A method to identify a specific binding partner compound of the PDE10 polynucleotide according to claim 5 comprising the steps of:
 - a) contacting the PDE10 polynucleotide with a compound under conditions which permit binding between the compound and the PDE10 polynucleotide;
 - b) detecting binding of the compound to the PDE10 polynucleotide; and
 - identifying the compound as a specific binding partner of the PDE10 polynucleotide.
- 29. The method according to claim 28 wherein the specific binding partner modulates expression of a PDE10 polypeptide encoded by the PDE10 polynucleotide.
- 30. The method according to claim 29 wherein the compound inhibits expression of the PDE10 polypeptide.
- 31. The method according to claim 29 wherein the compound enhances expression of the PDE10 polypeptide.
- $\label{eq:Acompound} 32. \qquad \text{A compound identified by the method according to claim} \\ 24 \text{ or } 28.$

33. A composition comprising the compound according to claim 32 and a pharmaceutically acceptable carrier.